All Stories

  1. The Kallikrein-Kinin System and Cardiovascular Diseases: A Narrative Review
  2. The Use of Colchicine in Cardiovascular Disease: Anti-Inflammatory Mechanisms and Clinical Utility
  3. Periodontal Disease and Cardiovascular Risk Factors
  4. Ascending Aorta Aneurysm: What the Cardiologist Needs to Know
  5. Chronic Obstructive Pulmonary Disease and Cardiovascular Disorders
  6. The neuro-cardiac axis in epilepsy
  7. Significant Stagnancy in the Search and Use of New Antiarrhythmic Agents With Some Recent Beams of Hope
  8. Circadian (diurnal/nocturnal) pattern of cardiac arrhythmias
  9. Emotional Stress in Cardiac and Vascular Diseases
  10. Metabolic dysfunction-associated steatotic liver disease and the cardiovascular system
  11. Cardiovascular Disorders in Systemic Lupus Erythematosus
  12. Atrial Fibrillation-Related Bradycardia and/or Bradycardia-Related Atrial Fibrillation: When and How to Intervene
  13. Cognitive Behavioral Therapy in Cardiovascular Disease
  14. Early-onset or Premature Coronary Artery Disease
  15. Permanent parahisian pacing is feasible, effective and more physiologic: no more right ventricular apical pacing and no compulsive need for elaborate His bundle pacing
  16. Sudden death in congenitally corrected transposition of the great vessels
  17. Are We Using Ezetimibe As Much As We Should?
  18. Role of Vitamins in Cardiovascular Health: Know Your Facts - Part 1
  19. Role of Vitamins in Cardiovascular Health: Know Your Facts-Part 2
  20. Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias
  21. Features of a Balanced Healthy Diet with Cardiovascular and Other Benefits
  22. Ketone Bodies and Cardiovascular Disease: An Alternate Fuel Source to the Rescue
  23. Neuropsychiatric disorders in patients with heart failure: not to be ignored
  24. Patients with Polyvascular Disease: A Very High-risk Group
  25. Diet and Sudden Death: How to Reduce the Risk
  26. Thrombus Aspiration in Acute Myocardial Infarction: A Long-Awaited Resurgence?
  27. High C-Reactive Protein/Low Serum Albumin: A Hidden Villain in Cardiovascular Disease
  28. Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis
  29. Takotsubo Syndrome and Sudden Cardiac Death
  30. Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition
  31. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk
  32. Electrocardiography of cardiac resynchronization therapy: Pitfalls and practical tips
  33. Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications
  34. COVID-19 Infection: A Neuropsychiatric Perspective
  35. The Cardiovascular Benefits of Caffeinated Beverages: Real or Surreal? / “Metron Ariston - All in Moderation”
  36. The role of the autonomic nervous system in cardiac arrhythmias: The neuro-cardiac axis, more foe than friend?
  37. COVID-19 and Acute Myocardial Injury and Infarction: Related Mechanisms and Emerging Challenges
  38. The proarrhythmic conundrum of alcohol intake
  39. Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
  40. COVID-19 infection and cardiac arrhythmias
  41. Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications
  42. Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases
  43. COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management
  44. Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?
  45. Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs)
  46. Editorial commentary: Premature heart disease mortality: A sobering reality calling for action
  47. Congenital heart block: Pace earlier (Childhood) than later (Adulthood)
  48. Cardiac arrhythmias in pregnant women: need for mother and offspring protection
  49. Atrial Fibrillation and Cognitive Impairment: An Associated Burden or Burden by Association?
  50. Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?
  51. Subclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call?
  52. Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives
  53. Cardiac amyloidosis: An underdiagnosed/underappreciated disease
  54. Cannabis Associated “High” Cardiovascular Morbidity and Mortality: Marijuana Smoke Like Tobacco Smoke? A Déjà Vu/Déjà Vécu Story?
  55. Pulmonary vein reconnection following cryo-ablation: Mind the “Gap” in the carinae and the left atrial appendage ridge
  56. Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target
  57. Editorial commentary: Prior silent/unrecognized myocardial infarction and heart failure: Size/extent matters
  58. Recommending marijuana use: Violation of the Hippocratic aphorism of “do good or do no harm”
  59. Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature
  60. Focal atrial tachycardia ablation: Highly successful with conventional mapping
  61. Psoriasis and cardiovascular disease: the elusive link
  62. Acute coronary syndromes in patients with angiographically normal or near normal (non-obstructive) coronary arteries
  63. Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2
  64. Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1
  65. Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale
  66. Echocardiography for the management of patients with biventricular pacing: Possible roles in cardiac resynchronization therapy implementation
  67. Use of intravenous vernakalant for atrial fibrillation conversion in the regular ward under only bedside monitoring
  68. Current Status of Renal Artery Angioplasty and Stenting for Resistant Hypertension: A Case Series and Review of the Literature
  69. Simplified percutaneous closure of patent foramen ovale and atrial septal defect with use of plain fluoroscopy: Single operator experience in 110 consecutive patients
  70. Pharmacologic inhibition of the mitochondrial Na + /Ca 2+ exchanger protects against ventricular arrhythmias in a porcine model of ischemia-reperfusion
  71. Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the “Low-Risk” Patients?
  72. Transseptal Access to the Left Atrium: Tips and Tricks to Keep it Safe Derived from Single Operator Experience and Review of the Literature
  73. Atrial antitachycardia pacing and atrial remodeling: A substudy of the international, randomized MINERVA trial
  74. Transcatheter aortic valve implantation in nonagenarians: selectively feasible or extravagantly futile?
  75. Transcatheter aortic valve implantation economics: a grisly reality
  76. Pre-loading therapy with statins in patients with angina and acute coronary syndromes undergoing PCI
  77. Electrophysiology Catheter-Facilitated coronary sinus cannulation and implantation of cardiac resynchronization therapy systems
  78. Percutaneous retrieval of a dislodged Amplatzer septal occluder device from the pulmonary artery with sole use of a snare and device lassoing
  79. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoameri...
  80. Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and...
  81. “Real life” longevity of implantable cardioverter-defibrillator devices
  82. Impact of Percutaneous Closure of Interatrial Shunts on Migraine Attacks: Single-Operator Series and Review of the Literature
  83. Assessing the Risk of Sudden Death in Patients with Non-Ischemic Dilated Cardiomyopathy
  84. Ablation of atrial fibrillation: single-shot techniques poised to dominate rhythm control strategies/the future is here
  85. Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS
  86. Cardiac implantable electronic device lead extraction using the lead-locking device system: keeping it simple, safe, and inexpensive with mechanical tools and local anesthesia
  87. Contemporary Diagnosis and Management of Atrial Flutter
  88. Prevention of Cardiac Implantable Electronic Device Infections: Single Operator Technique with Use of Povidone-Iodine, Double Gloving, Meticulous Aseptic/Antiseptic Measures and Antibiotic Prophylaxis
  89. 2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPEDIN COLLABORATION WITH EACTS
  90. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS
  91. Wytyczne ESC dotyczące leczenia migotania przedsionków w 2016 roku, opracowane we współpracy z EACTS
  92. Cryoballoon ablation of atrial fibrillation: a practical and effective approach
  93. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
  94. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
  95. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
  96. Simplified swift and safe vascular closure device deployment without a local arteriogram: Single center experience in 2074 consecutive patients
  97. The polymorphic deleted-form of the human α2B-adrenergic receptor and its wild-type counterpart display post-receptor signaling pathway differences in LLC-PK1 cells
  98. Exercise and Arrhythmias: A Double-Edged Sword
  99. Primary prevention of sudden cardiac death in Prinzmetal angina: The role of electrophysiology study in risk stratification
  100. In memoriam: The mentor, the teacher, the colleague, the healer, the scientist and friend: Kanu Chatterjee
  101. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society
  102. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society
  103. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial InfarctionClinical Perspective
  104. New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial
  105. Ranolazine and its Antiarrhythmic Actions
  106. Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial
  107. The clinical challenge of preventing sudden cardiac death immediately after acute ST-elevation myocardial infarction
  108. Central Sympathetic Inhibition to Reduce Postablation Atrial Fibrillation Recurrences in Hypertensive Patients
  109. Prospective European Survey on Atrial Fibrillation Ablation: Clinical Characteristics of Patients and Ablation Strategies Used in Different Countries
  110. Interatrial conduction time and incident atrial fibrillation: A prospective cohort study
  111. Association of asymmetric dimethylarginine levels with treadmill-stress-test-derived prognosticators
  112. Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial
  113. Anti-Inflammatory Treatment With Colchicine in Stable Chronic Heart Failure
  114. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: Mid-term efficacy and effect on quality of life
  115. Treating Dyslipidemias: Is Inflammation the Missing Link?
  116. Cardiac resynchronization therapy: Dire need for targeted left ventricular lead placement and optimal device programming
  117. Electrical Storm: Clinical Management
  118. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes
  119. Renoprotective Effect of Remote Ischemic Post-Conditioning by Intermittent Balloon Inflations in Patients Undergoing Percutaneous Coronary Intervention
  120. Colchicine Treatment for the Prevention of Bare-Metal Stent Restenosis in Diabetic Patients
  121. Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology
  122. Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
  123. 'Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper' [Europace 2012;14:124-134. doi: 10.1093/europace/eur338]
  124. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper
  125. Serum levels of ischemia modified albumin in overweight/obese postmenopausal women: A potential biomarker of atherosclerotic burden associated with oxidative stress
  126. 1-Year Outcome of TRIAS HR (TRI-Stent Adjudication Study–High Risk of Restenosis)
  127. Relation of Ventricular Tachycardia/Fibrillation to Beta-Blocker Dose Maximization Guided by Pacing Mode Analysis in Nonpacemaker-Dependent Patients With Implantable Cardioverter–Defibrillator
  128. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2 -receptor antagonist: the DILIPO study
  129. Novel sodium channel SCN5A mutations in Brugada syndrome patients from Greece
  130. Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?
  131. Anemia and Cardiovascular Disease
  132. Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes
  133. Arrhythmogenic Right Ventricular Cardiomyopathy in an Octogenarian Presenting with Ventricular Tachycardia
  134. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
  135. Lack of Association Between the Cholesteryl Ester Transfer Protein Gene—TaqIB Polymorphism and Coronary Restenosis Following Percutaneous Transluminal Coronary Angioplasty and Stenting: A Pilot Study
  136. Design and rationale of the TRI-stent Adjudication Study (TRIAS) Program
  137. Ischemia modified albumin, high-sensitivity c-reactive protein and natriuretic peptide in patients with coronary atherosclerosis
  138. Dabigatran versus Warfarin in Patients with Atrial Fibrillation
  139. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
  140. Correlation of Mechanical Dyssynchrony with QRS Duration Measured by Signal‐Averaged Electrocardiography
  141. The Rationale and Design of the Perindopril Genetic Association Study (PERGENE): A Pharmacogenetic Analysis of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with Stable Coronary Artery Disease
  142. Removal of a temporary pacemaker lead fragment with the use of biopsy forceps
  143. An unusual distal abdominal migration of a pacemaker pulse generator with a complete epicardial lead fracture
  144. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
  145. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
  146. The MINERVA study design and rationale: A controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias
  147. Left ventricular long-axis dysfunction in hypertensive patients
  148. Alternate Site Pacing in Patients at Risk for Heart Failure
  149. Association of the 894G>T polymorphism in the endothelial nitric oxide synthase gene with risk of acute myocardial infarction
  150. COAGULATION FACTORS VII AND VIII ARE INDEPENDENT PREDICTORS OF OXIDIZED LDL LEVELS IN NON ELDERLY PATIENTS WITH CORONARY ARTERY DISEASE
  151. Study of Left Ventricular Long Axis Function in Patients with Hypertensive Response to Exercise
  152. Letter by Tsilakis et al Regarding Article "Subclinical Left Ventricular Longitudinal Systolic Dysfunction in Hypertension With No Evidence of Heart Failure"
  153. The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population
  154. End-inspiratory occlusion maneuver during transesophageal echocardiography for patent foramen ovale detection in intensive care unit patients
  155. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT
  156. Improving SVT Discrimination in Single-Chamber ICDs: A New Electrogram Morphology-Based Algorithm
  157. Ivabradine: a Selective If Current Inhibitor in the Treatment of Stable Angina
  158. Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants
  159. Rethinking Target Discovery in Polygenic Diseases
  160. Transcatheter closure of patent foramen ovale during a radiofrequency ablation procedure
  161. Multi-Center Clinical Experience with a Lumenless, Catheter-Delivered, Bipolar, Permanent Pacemaker Lead: Implant Safety and Electrical Performance
  162. Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study
  163. Congestive Heart Failure and Anemia
  164. The Deleterious Consequences of Right Ventricular Apical Pacing: Time to Seek Alternate Site Pacing
  165. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial
  166. Lack of association between α2B-adrenergic receptor polymorphism and risk of restenosis following coronary angioplasty and stent implantation – preliminary report
  167. Wide-QRS-Complex Tachycardia with a Negative Concordance Pattern in the Precordial Leads: Are the ECG Criteria Always Reliable?
  168. Mo-P4:266 A simple peripheral atherosclerosis scoring system can readily predict the severity of coronary artery disease
  169. Mo-P1:99 Serum levels of oxidized low density lipoprotein relate to the extent and severity of coronary atherosclerosis in patients with coronary syndromes
  170. Site of successful slow pathway ablation relates to clinical tachycardia rate in patients with atrioventricular nodal re-entrant tachycardia
  171. The contrOL of dYslipideMia in outPatIent clinics in GreeCe (Olympic) Study
  172. Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
  173. Aspirin and Clopidogrel: A Sweeping Combination in Cardiology
  174. Release of endothelin-1 from human endocardium after radiofrequency catheter ablation and coronary angioplasty: comparative results
  175. Effects of oral pirenzepine on heart rate variability after acute myocardial infarction: A randomized trial
  176. Transvenous permanent pacing lead placement in the presence of prosthetic metallic tricuspid and mitral valves
  177. Accuracy of pulmonary function tests in predicted exercise capacity in COPD patients
  178. Well-Functioning Double-Orifice Mitral Valve in a Young Woman with Marfan-Like Habitus and Atrial Tachycardia
  179. Effects of Two Nebulization Regimens on Heart Rate Variability During Acute Asthma Exacerbations in Children
  180. Renal tumour with cavoatrioventricular extension
  181. Pulmonary valve staphylococcal endocarditis in a nondrug addict with alcoholic cirrhosis
  182. Clinical and pharmacological significance of α2-adrenoceptor polymorphisms in cardiovascular diseases
  183. Cardiac resynchronization therapy in congestive heart failure: Ready for prime time?
  184. Enzyme Replacement Therapy in Severe Fabry Disease with Renal Failure: A 1-year Follow-up
  185. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter
  186. Autonomic responses to single- and dual-chamber pacing
  187. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
  188. The bezold-jarisch reflex in acute inferior myocardial infarction: Clinical and sympathovagal spectral correlates
  189. P1548 Usefulness of ibutitilide in combination with propafenone for the conversion of atrial fibrillation
  190. Contribution of the sT elevation/T-wave normalization in q-wave leads during routine, pre-discharge treadmill exercise test to patient management and risk stratification after acute myocardial infarction
  191. Silent cardiac echinococcosis
  192. Comparative three-year performance of chronic atrial sensing among eight different VDD systems
  193. Arrhythmia recurrences are rare when the site of radiofrequency ablation of the slow pathway is medial or anterior to the coronary sinus os
  194. Single-lead VDD-pacing system incorporating high impedance stimulation: a multicentre study
  195. A reply
  196. Right ventricular cardiomyopathy in β-thalassaemia major
  197. In-vivo testing of digital cellular telephones in patients with implantable cardioverter-defibrillators
  198. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation
  199. The Prognostic Significance of Atrial Arrhythmias Recorded Early After Cardioversion for Atrial Fibrillation
  200. Diagnostic superiority of continuous-loop electrocardiographic recording over other testing in a patient with recurrent syncope and underlying coronary artery disease with severe left ventricular dysfunction
  201. Right ventricular diastolic function in β-thalassemia major: Echocardiographic and clinical correlates
  202. Ancillary Tools in Pacemaker and Defibrillator Lead Extraction Using a Novel Lead Removal System
  203. Reduced incidence of clinical restenosis with newer generation stents, stent oversizing, and high-pressure deployment: Single-operator experience
  204. Coronary artery calcification in patients with acute chest pain Dimitris Alexopoulos, Christos Stathopoulos, George Hahalis, John A. Chiladakis, Abraham Kotsaridis, Antonis S. Manolis. Patras University, Patras, Greece
  205. Weight loss after bariatric surgery normalizes Aortic distensibility and left ventricular function in subjects with morbid obesity Ignatios Ikonomidis, Andreas Mazarakis, Ioannis Chiladakis, Periklis Davlouros, George Hahalis, Costas Evdoridis, Fotis K...
  206. Autonomic Patterns Preceding and Following Accelerated Idioventricular Rhythm in Acute Myocardial Infarction
  207. Correction for Heart Rate Is Not Necessary for QT Dispersion in Individuals without Structural Heart Disease and Patients with Ventricular Tachycardia
  208. Two-Coil Versus Single-Coil Transvenous Cardioverter Defibrillator Systems: Comparative Data
  209. Dispersion of ventricular repolarization is determined by the presence of myocardial viability in patients with old myocardial infarction. A dobutamine stress echocardiography study
  210. Effects of early captopril therapy after myocardial infarction on the incidence of late potentials
  211. Significance of r-on-t phenomenon in early ventricular tachyarrhythmia susceptibility after acute myocardial infarction in the thrombolytic era
  212. Electrophysiologist-Implanted Transvenous Cardioverter Defibrillators Using Local Versus General Anesthesia
  213. Automatische Speicherung von Elektrogrammen zur Arrhythmie-Erfassung bei Patienten mit VDD-Schrittmacher
  214. Detection of myocardial injury during radiofrequency catheter ablation by measuring serum cardiac troponin I levels: procedural correlates
  215. Reply to the Editor:
  216. LETTERS TO THE EDITOR
  217. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial
  218. Pectoral Cardioverter Defibrillators: Comparison of Prepectoral and Submuscular Implantation Techniques
  219. Crataegus oxyacantha and Heart Failure
  220. Pretreatment with Antithrombotic Agents During Radiofrequency Catheter Ablation: A Randomized Comparison of Aspirin Versus Ticlopidine
  221. Unusual Features of Right and Left Idiopathic Ventricular Tachycardia Aholished hy Radiofrequency Catheter Ablation
  222. Successful Percutaneous Extraction of Pacemaker Leads With a Novel (VascoExtor) Pacing Lead Removal System
  223. Idiopathic long QT syndrome with late onset of bradycardia-dependent and short-coupled variant of torsade de pointes
  224. Beat-to-beat wavelet variance of the QRS complex as a marker of arrhythmogenic substrate in ventricular tachycardia patients
  225. Atrial Arrhythmias Early After Cardioversion Predict Recurrence of Atrial Fibrillation
  226. Randomized Comparison of the Effect of Aspirin Versus Ticlopidine on the Thrombogenic Potential of Radiofrequency Ablation
  227. Successful Radiofrequency Catheter Ablation of Automatic Atrial Tachycardia with Regression of the Cardiomyopathy Picture
  228. Comparison of Signal-Averaged Electrocardiograms with Different Levels of Noise: Time-Domain, Frequency-Domain, and Spectrotemporal Analysis
  229. Transvenous defibrillator systems implanted by electrophysiologists in the catheterization laboratory
  230. Pretreatment With Aspirin and Ticlopidine Confers Lower Thrombogenic Potential of Radiofrequency Catheter Ablation
  231. Abnormal signal-averaged electrocardiograms in patients with incomplete right bundle-branch block
  232. Thrombogenicity of radiofrequency lesions: Results with serial D-dimer determinations
  233. Perioperative and Long-term Results With Mapping-Guided Subendocardial Resection and Left Ventricular Endoaneurysmorrhaphy
  234. Radiofrequency Ablation of Atrial Insertion of Left-Sided Accessory Pathways Guided by the "W Sign"
  235. Implantable Cardioverter-Defibrillators
  236. Radiofrequency ablation of slow pathway in patients with atrioventricular nodal reentrant tachycardia. Do arrhythmia recurrences correlate with persistent slow pathway conduction or site of successful ablation?
  237. Radiofrequency ablation of left-sided accessory pathways: Transaortic versus transseptal approach
  238. Fully transvenous cardioverter defibrillators: Rare need for subcutaneous patch with two newer-generation systems
  239. Radiofrequency Catheter Ablation for Cardiac Tachyarrhythmias
  240. Antitachycardia pacing and low-energy cardioversion for ventricular tachycardia termination: A clinical perspective
  241. Transvenous Endocardial Cardioverter Defibrillator Systems
  242. Transvenous endocardial cardioverter defibrillator systems. Is the future here?
  243. Plasma level changes of fibrinopeptide a after uncomplicated coronary angioplasty
  244. Effects of Coronary Artery Bypass Grafting on Ventricular Arrhythmias: Results with Electrophysiological Testing and Long-Term Follow-Up
  245. Electrophysiological and electropharmacological studies in pre-excitation syndromes: results with propafenone therapy and isoproterenol infusion testing
  246. Effect of Successful Coronary Angioplasty on the Signal-Averaged Electrocardiogram
  247. Cost-effectiveness of the implantable cardioverter-defibrillator: Effect of improved battery life and comparison with amiodarone therapy
  248. Magnetic Field Interference in High-Resolution Electrocardiography
  249. Limited clinical utility of endomyocardial biopsy in patients presenting with ventricular tachycardia without apparent structural heart disease
  250. Inappropriate Shocks and Elevation of Defibrillation Thresholds in a Patient with Automatic Defibrillator Patch Silastic Erosion and Titanium Mesh Fraying
  251. Apical hypertrophic cardiomyopathy presenting with sustained monomorphic ventricular tachycardia and electrocardiographic changes simulating coronary artery disease and left ventricular aneurysm
  252. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease
  253. Syncope: Current Diagnostic Evaluation and Management
  254. Mexiletine: Pharmacology and therapeutic use
  255. Randomized double-blind study of intravenous tocainide versus lidocaine for suppression of ventricular arrhythmias after cardiac surgery
  256. Value of programmed ventricular stimulation in the evaluation and management of patients with nonsustained ventricular tachycardia associated with coronary artery disease
  257. Automatic Implantable Cardioverter Defibrillator
  258. Automatic implantable cardioverter defibrillator. Current status
  259. Clinical experience in seventy-seven patients with the automatic implantable cardioverter defibrillator
  260. Pacemakers and Exercise Current Status, Future Developments and Practical Implications of Physiological Pacemakers
  261. Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome
  262. Surgical therapy for drug-refractory ventricular tachycardia: Results with mapping-guided subendocardial resection
  263. Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion
  264. Prognostic value of early electrophysiologic studies for ventricular tachycardia recurrence in patients with coronary artery disease treated with amiodarone
  265. Prophylactic automatic implantable cardioverter-defibrillator patches in patients at high risk for postoperative ventricular tachyarrhythmias
  266. Electrophysiologic effects, efficacy and tolerance of class Ic antiarrhythmic agents in Wolff-Parkinson-White syndrome
  267. External cardiac programmed stimulation for noninvasive termination of sustained supraventricular and ventricular tachycardia
  268. Echocardiographic and Clinical Correlates in Drug Addicts With Infective Endocarditis
  269. Echocardiographic and clinical correlates in drug addicts with infective endocarditis. Implications of vegetation size
  270. Necropsy study of right atrial appendage: Morphology and quantitative measurements
  271. Sensitivity and specificity of programmed atrial stimulation for induction of supraventricular tachycardias
  272. Short-Term Hemodynamic Effects of Intravenous Methyldopa in Patients with Congestive Heart Failure
  273. Supraventricular Tachycardia
  274. Atypical Pulmonary and Neurologic Complications of Amiodarone in the Same Patient
  275. Supraventricular tachycardia. Mechanisms and therapy
  276. Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature
  277. Childhood periodic paralysis with dysrhythmias: Electrophysiologic and histopathologic evaluation
  278. Pacemaker Wenckebach secondary to variable latency: An unusual form of hyperkalemic pacemaker exit block
  279. Hypothyroid Cardiac Tamponade
  280. Hypothyroid cardiac tamponade
  281. Orthostatic hypotension due to quinidine and atenolol
  282. Cardiopathia fantastica and arteritis factitia as manifestations of Munchausen syndrome
  283. Selective noise filtering of high resolution ECG through wavelet transform
  284. Comparison of heart rate variability parameters calculated by two different commercial analysis systems
  285. Short-term reproducibility of the time and frequency domain parameters of heart rate variability